Clinical trial
Study of Treatment High Risk and/or Low Risk Acute Lymphoblastic leukémia(ALL)…
NCT00483132 · French Innovative Leukemia Organisation, Other · Completed
Key facts
| NCT number | NCT00483132 |
|---|---|
| Title | Study of Treatment High Risk and/or Low Risk Acute Lymphoblastic leukémia(ALL) Adults Stage III |
| Official title | Study of Treatment High Risk and/or Low Risk Acute Lymphoblastic leukémia(ALL) Adults Stage III |
| Lead sponsor | French Innovative Leukemia Organisation, Other |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Leukemia, Lymphocytic, Acute |
| Intervention type | Drug |
| Interventions | interferon alpha 2a |
| Enrollment | 232 |
| Start date | Sep 1, 1994 |
| Completion | Apr 1, 2002 |
| First posted | Jun 6, 2007 |
| Last update posted | Jun 6, 2007 |
| Countries | France |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: